SCHEDULE: Pfizer Discloses 3.0% Stake in NEXTCURE, INC.

Pfizer Inc. and its affiliate Pfizer Ventures (US) LLC have reported a combined beneficial ownership of 3.0% in NEXTCURE, INC. common stock.

Summary

• Pfizer Inc. and its controlled affiliate, Pfizer Ventures (US) LLC, have filed an Amendment No. 1 to Schedule 13G, reporting their beneficial ownership in NEXTCURE, INC.
• Pfizer Inc. beneficially owns an aggregate of 157,646 shares of NEXTCURE, INC. common stock, representing 3.0% of the class outstanding.
• Pfizer Ventures (US) LLC beneficially owns 131,109 shares, representing 2.5% of the class outstanding, over which Pfizer Inc. has shared voting and dispositive power.
• The percentage of class outstanding is based on a total of 5,203,290 shares of common stock, including 1,815,049 shares issuable upon exercise of Pre-Funded Warrants, as reported in NEXTCURE's final prospectus filed on December 11, 2025.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of NEXTCURE, INC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively for NEXTCURE, INC. as it signals a notable investment from a major pharmaceutical company, Pfizer, which can enhance market confidence and potentially open doors for future strategic opportunities, despite being a passive stake.

Positives

• A significant pharmaceutical company like Pfizer Inc. holding a stake in NEXTCURE, INC. can be viewed as a vote of confidence in NEXTCURE's potential and strategic direction.
• Pfizer's investment, even if passive, could signal potential future collaborations or strategic interest, enhancing NEXTCURE's credibility in the biotech sector.

Negatives

• The filing itself does not contain any negative financial or operational information about NEXTCURE, INC.

Risks

• The filing does not detail specific risks related to NEXTCURE, INC.'s operations or financial health, as it is a beneficial ownership report.

Future Outlook

The filing is a beneficial ownership report and does not provide forward-looking statements or guidance regarding NEXTCURE, INC.'s future performance or operations.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing from a major pharmaceutical player like Pfizer Inc. indicating a passive stake in a biotechnology company such as NEXTCURE, INC. is a common occurrence in the life sciences sector. Large pharmaceutical companies often invest in smaller biotech firms to gain exposure to innovative research and development, potentially scouting for future partnerships, licensing agreements, or acquisition targets. This type of investment can lend significant validation to the smaller company's scientific platform and pipeline.

Related Party Transactions

• Pfizer Ventures (US) LLC is a controlled affiliate of Pfizer Inc., and their beneficial ownership is reported collectively, indicating an intra-group holding structure.

Stakeholder Impact

• Shareholders of NEXTCURE, INC. may view Pfizer's stake as a positive indicator of the company's long-term potential and strategic value.
• The investment could attract further institutional interest in NEXTCURE, INC.

Key Dates

Recommendation

A seasoned investor would likely maintain a 'hold' recommendation based solely on this filing. While Pfizer's stake is a positive signal, a Schedule 13G indicates a passive investment, not an active strategic move or a change in company fundamentals. It provides validation but does not inherently change the investment thesis for NEXTCURE, INC. without further operational or financial updates. Investors would need to evaluate NEXTCURE's core business, pipeline, and financial performance independently.

Keywords

NEXTCURE, Pfizer, Pfizer Ventures, Biotechnology, Pharmaceuticals, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Investment